



(51) International Patent Classification:

C07D 401/04 (2006.01) A61K 31/421 (2006.01)
 C07D 403/04 (2006.01) A61K 31/427 (2006.01)
 C07D 413/04 (2006.01) A61K 31/437 (2006.01)
 C07D 413/14 (2006.01) A61K 31/4439 (2006.01)
 C07D 417/04 (2006.01) A61P 25/18 (2006.01)
 C07D 471/04 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/EP2012/065140

(22) International Filing Date:

2 August 2012 (02.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11176468.4 3 August 2011 (03.08.2011) EP

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GIOVANNINI, Riccardo** [IT/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **BERTANI, Barbara** [IT/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **FERRARA, Marco** [IT/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **LINGARD, Iain** [GB/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE). **MAZZAFERRO, Rocco** [IT/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim

heim Am Rhein (DE). **ROSENBROCK, Holger** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(74) Agents: **SIMON, Elke** et al.; Boehringer Ingelheim GmbH, Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PHENYL-3-AZA-BICYCLO[3.1.0]HEX-3-YL-METHANONES AND THE USE THEREOF AS MEDICAMENT



(I)

(57) Abstract: The present inventions relates to substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl- methanones of general formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ are as herein described or salts thereof, preferably pharmaceutically acceptable salts thereof. The invention further relates to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various conditions such as conditions concerning positive and negative symptoms of schizophrenia as well as cognitive impairments associated with schizophrenia, Alzheimers Disease and other neurological and psychiatric disorders. The compounds of the invention show glycine transporter-1 (GlyT1) inhibiting properties.